OTLK
Outlook Therapeutics, Inc. Common Stock
stockNASDAQ
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team's biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics' platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company's most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.47 | 2026-11-02 | -7.30% | 0.854 |
| 1M | 0.60 | 2026-10-09 | -27.38% | 2.044 |
| 3M | 1.15 | 2026-08-10 | -62.18% | 1.828 |
| 6M | 0.22 | 2026-05-08 | +96.54% | 1.113 |
| 1Y | 1.26 | 2025-11-10 | -65.48% | 0.966 |
| 2Y | 6.32 | 2024-11-08 | -93.12% | — |
| 5Y | 41.40 | 2021-11-09 | -98.95% | 0.976 |
Outlook Therapeutics, Inc. Common Stock (NASDAQ:OTLK) stock price today is $0.43, and today's volume is 1,636,434. OTLK is down 0.945% today. The 30 day average volume is 4.18M. OTLK market cap is $105.89M with 243.45M shares outstanding.